BioSpace News Archive

Oragenics, Inc. announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular and intranasal adjuvants.

PetVivo Holdings, Inc. an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced it will be exhibiting at the Western Veterinary Conference to be held September 6th to September 9th, 2021 at the Mandalay Bay Convention Center in Las Vegas, Nevada.

EnZen Therapeutics, Inc. today announced that EnZen has invested in Thirona under a convertible promissory note arrangement.

SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced that effective August 27, 2021, it has granted an aggregate of 3,385,000 stock options to a consultant and certain employees and officers of the Company under the Company’s amended and restated stock option plan.

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the appointment of Kevin S. Boyle, Sr. as its new Chief Executive Officer, effective today.

Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials, announced its participation in the H. C. Wainwright 23rd Annual Global Investment Conference.

Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of approximately $15 million.

Physicians from four medical centers recently published data this month from an initial six patients implanted with CivaSheet® to treat retroperitoneal sarcoma.

SOPHiA GENETICS SA (Nasdaq: SOPH), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE ® as a treatment for mild-to-moderate COVID-19.